Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000761742 | SCV000891927 | uncertain significance | not provided | 2024-06-01 | criteria provided, single submitter | clinical testing | |
New York Genome Center | RCV001836877 | SCV002097950 | uncertain significance | Cutis laxa, autosomal dominant 3 | 2021-02-19 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003768293 | SCV002135508 | uncertain significance | Cutis laxa, autosomal dominant 3; Autosomal dominant spastic paraplegia type 9; de Barsy syndrome | 2024-09-30 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 451 of the ALDH18A1 protein (p.Val451Met). This variant is present in population databases (rs111344269, gnomAD 0.008%). This missense change has been observed in individual(s) with ALDH18A1-related conditions (PMID: 37712079). ClinVar contains an entry for this variant (Variation ID: 623751). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed for this missense variant. However, the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on ALDH18A1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Revvity Omics, |
RCV000761742 | SCV003823123 | uncertain significance | not provided | 2019-12-19 | criteria provided, single submitter | clinical testing | |
Neurogenomics Lab, |
RCV003320368 | SCV003930351 | uncertain significance | Autosomal recessive complex spastic paraplegia type 9B | 2024-05-22 | criteria provided, single submitter | research | PM2_supporting: The highest population allele frequency in gnomAD v4.0 is 0.00007811 (0.008%; 5/64012 alleles in European Finnish population). This variant is absent from gnomAD v2.1.1 (adequate coverage >20x confirmed) and an internal database of 1074 control alleles. PM1 met: variant occurs in the G5PR functional domain together with other recessive pathogenic variants. |
Gene |
RCV000761742 | SCV005383541 | uncertain significance | not provided | 2024-02-15 | criteria provided, single submitter | clinical testing | Identified in apparently homozygous state in a patient with hereditary spastic paraplegia (HSP) (PMID: 37712079); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 37712079) |